We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Analysis Links Transporter Protein to Alzheimer's Disease

By Biotechdaily staff writers
Posted on 01 Jun 2004
Researchers have used amplified differential gene expression (ADGE) and ADGE microarray technology to examine cell lines made to express high levels of human ABCA2 transporter protein. More...
Human ABCA2 transporter is a member of a large family of ATP-binding proteins that transport a variety of macromolecules across biologic membranes and, more specifically, its overexpression has been implicated in the acquired resistance of cells to the chemotherapeutic drug estramustine.

Investigators at Fox Chase Cancer Center (Philadelphia, PA, USA) designed ADGE to quadratically magnify the ratios of genes in two samples with the integration of DNA reassociation and polymerase chain reaction (PCR). Quadratic magnification and PCR amplification of templates improve the sensitivity and accuracy of gene expression profiling. ADGE microarray combines the high throughput of microarray and the sensitivity and accuracy of ADGE. Compared to regular microarray, ADGE microarray improves the sensitivity and accuracy of gene expression profiling, enhances the signal intensities, and requires less starting material.
Using these methods to study a line of cells genetically engineered to overexpress the gene for ABCA2, the investigators reported in the May 20, 2004, online edition of the Federation of American Societies for Experimental Biology Journal that the ABCA2 transfected cell line expressed resistance to a free radical initiator. This finding confirmed the involvement of this protein in protection against reactive oxygen species and suggested a possible link to Alzheimer's disease.
"The overexpression of the ABCA2 protein has been implicated in acquired resistance of tumors to the drug estramustine, which is used to treat prostate cancer patients,” explained senior author Dr. Kenneth D. Tew, now chairman of the department of cell and molecular pharmacology and experimental therapeutics at the Medical University of South Carolina (Charleston, USA). "This transporter is also expressed at high levels in brain tissue and may be linked with the transport of molecules relevant to the etiology of Alzheimer's disease, including those involved in the formation of amyloid plaques.

The association of the transporter with Alzheimer's first emerged from a comparative gene expression pattern analysis that we did. In samples of brain sections from Alzheimer's patients, the ABCA2 protein shows unusual patterns. That also suggests that this transporter has a possible role in Alzheimer's.”
Fox Chase Cancer Center >> www.fccc.edu




Related Links:
Medical University of South Carolina

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.